WELCOME
On the following pages we would like to introduce Onkonetz Hamburg-Holstein as a cooperation partner of several networks of regional hospitals, in particular the Tumor Center Hamburg as a Comprehensive Cancer Center and the team of outpatient specialist care “Onkonetz” of the Asklepios Klinikum Barmbek.
Within the network structures, we guarantee comprehensive care for tumour patients according to the latest standards in close coordination with the inpatient and outpatient cooperation partners on the basis of various organizational structures (medical care centers, §116b outpatient clinics and freelance statutory health insurance physicians).
All doctors at the care locations are specialists in internal medicine, hematology and internal oncology with many years of experience.
The latest scientific and research findings are always passed on to patients through regular further training and membership and participation in specialist associations and organizations.
All decisions following the initial diagnosis of blood or tumor diseases are made in regional tumor conferences with the influence of specialists from other disciplines and hospitals.
Registered nurses with several years of oncology expertise are employed in the chemotherapy department.
The Onkonetz Hamburg-Holstein is divided into two practice units: The Reinbek practice and the Bergedorf practice. We wish all our patients a speedy recovery
oncology 
Coagulation medicine Hematology As in Bergedorf, Dr. Fritz and his colleagues in Reinbek treat tumor patients on a freelance basis.
The Reinbek site was one of the first to be established in eastern Hamburg in 2001.
As in Bergedorf, joint patient management with the regional oncology specialist hospitals enables patients to be treated close to home with complex therapy concepts.
The capacity is 3,000 patients per year.
We have been offering outpatient services in the field of hematology and oncology in Hamburg-Bergedorf since 2006.
Together with Dr. Fritz, the practice is a cooperation partner in the field of freelance health insurance care.
Up to 2,500 patients are treated annually.
In contrast to conventional chemotherapy-based therapy methods, which are based on the respective diseased organs (stomach, intestines, lungs, breast, etc.), modern targeted cancer therapy uses stereotypical tumor characteristics that can be the same for different tumor types.
The treatments use changes (mutations) in the tumor genome (tyrosine kinase inhibitors), tumor surface characteristics (antibody therapy) or mechanisms of tumor camouflage (immune checkpoint inhibitors) and specific tumor metabolic processes, and are generally much better tolerated than classic chemotherapies.
Their response is often more profound and longer-lasting in the metastatic situation.
As a result, many metastatic cancers lose their terror, as they can be transformed into a chronic disease through treatment options with few side effects and the symptoms of the disease can be controlled over a long period of time.
Cancer is thus increasingly becoming a chronic disease like diabetes, which cannot yet be cured, but with which it is possible to live well and with a good state of health.
Increasingly, these innovative drugs are already approved and can be used for initial treatment.
As a result, traditional chemotherapy is becoming less and less important.
More and more modern preparations are also available for neoadjuvant and adjuvant therapy before or after tumor surgery.
In addition to conventional chemotherapy, which continues to play an important role in the various tumor entities depending on the type and stage of the cancer, the following drugs are used in particular
The individual use of targeted therapy requires knowledge of the relevant molecular tumor characteristics, i.e. the detection of driver mutations, surface antigens and specific metabolic processes.
The molecular analyses are carried out in so-called panel procedures, in which the most frequent tumour mutations are recorded in a standardized manner for the purposes of screening.
These tests are routinely performed on the patients we care for together with tumor centers at the time of initial diagnosis or are arranged by us, because: The sooner the relevant results are available, the sooner targeted treatment can be provided.
In the case of advanced diseases or second opinion requests, the analyses are requested by us.
onkonetz hamburg-holstein
Schönningstedter Straße 49
21465 Reinbek
Telephone: 0 40 / 7 80 89 06
Telefax: 0 40 / 78 08 90 85
info@onkonetz-hh.de
onkonetz hamburg-holstein
Weidenbaumsweg 19
21029 Hamburg
Telephone: 0 40 / 416 26 50
Telefax: 0 40 / 416 265 21
info@onkonetz-hh.de
info@onkonetz-hh.de
dr.fritz@onkonetz-hh.de
r.nerge@onkonetz-hh.de
k.meyer-stender@onkonetz-hh.de
s.panzer@onkonetz-hh.de
sekretariat@onkonetz-hh.de
